- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 658126, 8 pages
Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses
1Department of Radiation Oncology, University of Washington, 1959 NE Pacific Street, P.O. Box 356043, Seattle, WA 98195, USA
2Department of Radiation Oncology & Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD 21218, USA
3Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD 21218, USA
4Department of Neurosurgery, Johns Hopkins Medicine, Baltimore, MD 21218, USA
5Department of Urology, Johns Hopkins Medicine, Baltimore, MD 21218, USA
Received 16 June 2013; Revised 5 October 2013; Accepted 5 October 2013
Academic Editor: Rumiana Koynova
Copyright © 2013 Jing Zeng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, “Cancer immunoediting: from immunosurveillance to tumor escape,” Nature Immunology, vol. 3, no. 11, pp. 991–998, 2002.
- R. D. Schreiber, L. J. Old, and M. J. Smyth, “Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion,” Science, vol. 331, no. 6024, pp. 1565–1570, 2011.
- P. Matzinger, “Tolerance, danger, and the extended family,” Annual Review of Immunology, vol. 12, pp. 991–1045, 1994.
- S. E. A. Street, E. Cretney, and M. J. Smyth, “Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis,” Blood, vol. 97, no. 1, pp. 192–197, 2001.
- B. A. Pulaski, M. J. Smyth, and S. Ostrand-Rosenberg, “Interferon-γ-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma,” Cancer Research, vol. 62, no. 15, pp. 4406–4412, 2002.
- T. Luft, K. C. Pang, E. Thomas et al., “Type I IFNs enhance the terminal differentiation of dendritic cells,” Journal of Immunology, vol. 161, no. 4, pp. 1947–1953, 1998.
- G. P. Sims, D. C. Rowe, S. T. Rietdijk, R. Herbst, and A. J. Coyle, “HMGB1 and RAGE in inflammation and cancer,” Annual Review of Immunology, vol. 28, pp. 367–388, 2010.
- G. P. Dunn, L. J. Old, and R. D. Schreiber, “The three Es of cancer immunoediting,” Annual Review of Immunology, vol. 22, pp. 329–360, 2004.
- W. Zou, “Immunosuppressive networks in the tumour environment and their therapeutic relevance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 263–274, 2005.
- C. G. Drake, “Combination immunotherapy approaches,” Annals of Oncology, vol. 23, supplement 8, pp. 41–46, 2012.
- C. E. Hill-Kayser, J. P. Plastaras, Z. Tochner, and E. Glatstein, “TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions,” Bone Marrow Transplantation, vol. 46, no. 4, pp. 475–484, 2011.
- J. L. Campian, X. Ye, M. Brock, et al., “Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer,” Cancer Investigation, vol. 31, no. 3, pp. 183–188, 2013.
- L. Harisiadis, G. Kopelson, and C. H. Chang, “Lymphopenia caused by cranial irradiation in children receiving craniospinal radiotherapy,” Cancer, vol. 40, no. 3, pp. 1102–1108, 1977.
- S. Yovino, L. Kleinberg, S. A. Grossman, M. Narayanan, and E. Ford, “The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells,” Cancer Investigation, vol. 31, no. 2, pp. 140–144, 2013.
- S. Demaria and S. C. Formenti, “Sensors of ionizing radiation effects on the immunological microenvironment of cancer,” International Journal of Radiation Biology, vol. 83, no. 11-12, pp. 819–825, 2007.
- A. Melcher, S. Todryk, N. Hardwick, M. Ford, M. Jacobson, and R. G. Vile, “Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression,” Nature Medicine, vol. 4, no. 5, pp. 581–587, 1998.
- M. Obeid, A. Tesniere, F. Ghiringhelli et al., “Calreticulin exposure dictates the immunogenicity of cancer cell death,” Nature Medicine, vol. 13, no. 1, pp. 54–61, 2007.
- L. Apetoh, F. Ghiringhelli, A. Tesniere et al., “Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy,” Nature Medicine, vol. 13, no. 9, pp. 1050–1059, 2007.
- S. Demaria, F. R. Santori, B. Ng, L. Liebes, S. C. Formenti, and S. Vukmanovic, “Select forms of tumor cell apoptosis induce dendritic cell maturation,” Journal of Leukocyte Biology, vol. 77, no. 3, pp. 361–368, 2005.
- S. C. Formenti and S. Demaria, “Radiation therapy to convert the tumor into an in situ vaccine,” International Journal of Radiation Oncology. Biology. Physics, vol. 84, no. 4, pp. 879–880.
- E. A. Reits, J. W. Hodge, C. A. Herberts et al., “Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy,” Journal of Experimental Medicine, vol. 203, no. 5, pp. 1259–1271, 2006.
- C. T. Garnett, C. Palena, M. Chakarborty, K.-Y. Tsang, J. Schlom, and J. W. Hodge, “Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes,” Cancer Research, vol. 64, no. 21, pp. 7985–7994, 2004.
- M. Chakraborty, S. I. Abrams, K. Camphausen et al., “Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy,” Journal of Immunology, vol. 170, no. 12, pp. 6338–6347, 2003.
- S. Demaria, B. Ng, M. L. Devitt et al., “Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated,” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 3, pp. 862–870, 2004.
- J. Zeng, A. P. See, J. Phallen, et al., “Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas,” International Journal of Radiation Oncology Biology Physics, vol. 86, no. 2, pp. 343–349, 2013.
- M. Z. Dewan, A. E. Galloway, N. Kawashima et al., “Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody,” Clinical Cancer Research, vol. 15, no. 17, pp. 5379–5388, 2009.
- S. Demaria, N. Kawashima, A. M. Yang et al., “Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer,” Clinical Cancer Research, vol. 11, no. 2 I, pp. 728–734, 2005.
- I. Verbrugge, J. Hagekyriakou, L. L. Sharp, et al., “Radiotherapy increases the permissiveness of established mammary tumors to rejecton by immunomodulatory antibodies,” Cancer Research, vol. 72, no. 13, pp. 3163–3174, 2012.
- E. Younes, G. P. Haas, B. Dezso et al., “Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma,” Cellular Immunology, vol. 165, no. 2, pp. 243–251, 1995.
- T. J. Harris, E. L. Hipkiss, S. Borzillary et al., “Radiotherapy augments the immune response to prostate cancer in a time-dependent manner,” Prostate, vol. 68, no. 12, pp. 1319–1329, 2008.
- J. L. Gulley, P. M. Arlen, and A. Bastian, “Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer,” Clinical Cancer Research, vol. 11, no. 9, pp. 3353–3362, 2005.
- K.-H. Chi, S.-J. Liu, C.-P. Li et al., “Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma,” Journal of Immunotherapy, vol. 28, no. 2, pp. 129–135, 2005.
- Y. H. Kim, D. Gratzinger, C. Harrison et al., “In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study,” Blood, vol. 119, no. 2, pp. 355–363, 2012.
- S. K. Seung, B. D. Curti, M. Crittenden, et al., “Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses,” Science Translational Medicine, vol. 4, no. 137, p. 137ra74.
- M. A. Postow, M. K. Callahan, C. A. Barker et al., “Immunologic correlates of the abscopal effect in a patient with melanoma,” New England Journal of Medicine, vol. 366, no. 10, pp. 925–931, 2012.
- S. M. Hiniker, D. S. Chen, S. Reddy, et al., “A systemic complete response of metastatic melanoma to local radiation and immunotherapy,” Translational Oncology, vol. 5, no. 6, pp. 404–407, 2012.
- S. F. Slovin, C. S. Higano, O. Hamid, et al., “Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study,” Annals of Oncology, vol. 24, no. 7, pp. 1813–1821, 2013.
- D. Schaue, J. A. Ratikan, K. S. Iwamoto, and W. H. McBride, “Maximizing tumor immunity with fractionated radiation,” International Journal of Radiation Oncology Biology Physics, vol. 83, no. 4, pp. 1306–1310, 2012.
- Y. Lee, S. L. Auh, Y. Wang et al., “Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment,” Blood, vol. 114, no. 3, pp. 589–595, 2009.
- S. Demaria and S. C. Formenti, “Radiation as an immunological adjuvant: current evidence on dose and fractionation,” Frontiers in Oncology, vol. 2, p. 153, 2012.
- S. S. Ahmad, “Advances in radiotherapy,” British Medical Journal, vol. 345, Article ID e7765, 2012.
- Y. Rong and J. Welsh, “Basics of particle therapy II biologic and dosimetric aspects of clinical Hadron therapy,” American Journal of Clinical Oncology, vol. 33, no. 6, pp. 646–649, 2010.